

**SUPPLEMENTARY TABLE 1. Estimated vaccination coverage by age 24 months\* among children born 2018-2019,<sup>†</sup> by selected vaccines and doses and race/ethnicity,<sup>§</sup> National Immunization Survey-Child, United States, 2019-2021**

Vaccine/No. doses	% (95% CI), by Race/Ethnicity						
	White, non-Hispanic (referent) (n = 17,214)	Black, non-Hispanic (n = 2,295)	Hispanic or Latino (Hispanic) (n = 5,608)	American Indian/Alaska Native, non-Hispanic (n = 347)	Asian, non-Hispanic (n = 1,472)	Native Hawaiian or other Pacific Islander, non-Hispanic (n = 115)	Multiple Race, non-Hispanic (n = 2,547)
<b>DTaP<sup>¶</sup></b>							
≥3 doses	95.1 (94.3–95.8)	90.9 (88.7–92.8)**	94.1 (92.9–95.2)	91.3 (85.5–95.4)	97.1 (95.3–98.3)**	90.4 (81.3–96.2)	93.3 (90.9–95.3)
≥4 doses	83.9 (82.6–85.1)	74.7 (71.6–77.7)**	81.9 (79.7–84.0)	76.3 (67.8–83.9)	87.2 (83.7–90.3)	— <sup>††</sup>	79.2 (75.5–82.6)**
<b>Poliovirus (≥3 doses)</b>	94.1 (93.3–94.9)	89.8 (87.6–91.8)**	93.4 (92.0–94.5)	91.2 (85.4–95.4)	96.9 (95.2–98.2)**	90.4 (81.3–96.2)	92.8 (90.4–94.8)
<b>MMR (≥1 dose)<sup>§§</sup></b>	93.1 (92.2–93.9)	88.1 (85.7–90.3)**	90.6 (88.9–92.1)**	90.2 (84.8–94.4)	94.7 (92.2–96.6)	— <sup>††</sup>	91.0 (88.6–93.1)
<b>Hib<sup>¶¶</sup></b>							
Primary series	94.5 (93.7–95.3)	90.2 (88.0–92.1)**	93.2 (91.9–94.4)	91.9 (86.1–95.9)	96.3 (94.2–97.8)	90.2 (81.0–96.1)	93.0 (90.7–95.0)
Full series	81.9 (80.5–83.2)	72.6 (69.4–75.7)**	80.3 (78.1–82.4)	73.6 (64.7–81.8)	83.3 (79.1–87.1)	— <sup>††</sup>	78.7 (75.3–82.0)
<b>HepB</b>							
Birth dose <sup>***</sup>	78.5 (77.0–79.8)	77.2 (73.9–80.2)	81.8 (79.6–83.7)**	83.5 (75.3–89.3)	83.3 (79.2–86.8)**	— <sup>††</sup>	82.2 (79.2–84.8)**
≥3 doses	93.5 (92.6–94.2)	90.0 (87.8–91.9)**	92.0 (90.7–93.2)	91.4 (85.3–95.7)	96.2 (94.0–97.8)**	93.8 (87.0–97.7)	92.4 (90.1–94.3)
<b>VAR (≥1 dose)<sup>§§</sup></b>	92.6 (91.7–93.5)	88.2 (85.8–90.4)**	89.8 (88.1–91.4)**	90.4 (84.7–94.7)	94.9 (92.5–96.6)	— <sup>††</sup>	88.4 (85.1–91.2)**
<b>PCV</b>							
≥3 doses	94.2 (93.4–95.0)	89.8 (87.6–91.8)**	93.3 (92.0–94.5)	90.4 (84.5–94.7)	95.7 (93.4–97.4)	90.4 (81.3–96.2)	92.6 (90.1–94.6)
≥4 doses	85.5 (84.2–86.7)	76.4 (73.4–79.3)**	83.4 (81.4–85.3)	73.0 (64.1–81.3)**	87.2 (83.9–90.1)	— <sup>††</sup>	83.3 (80.3–86.1)
<b>HepA</b>							
≥1 dose	88.4 (87.3–89.5)	84.3 (81.6–86.8)**	89.6 (88.0–91.1)	88.1 (82.0–92.9)	92.5 (89.8–94.7)**	— <sup>††</sup>	87.0 (84.3–89.4)
≥2 doses <sup>†††</sup>	46.9 (45.3–48.5)	45.0 (41.3–48.9)	48.6 (45.8–51.4)	— <sup>††</sup>	50.8 (46.0–55.8)	— <sup>††</sup>	46.0 (42.0–50.2)
≥2 doses (by 35 months) <sup>†††</sup>	80.6 (78.5–82.6)	75.8 (71.3–80.0)	79.0 (75.6–82.2)	83.1 (71.6–91.8)	85.4 (80.6–89.6)	— <sup>††</sup>	77.1 (72.4–81.5)
<b>Rotavirus (by 8 months)<sup>§§§</sup></b>	79.8 (78.4–81.1)	68.8 (65.4–72.0)**	76.7 (74.3–78.8)**	68.5 (58.8–76.8)**	80.0 (75.7–83.8)	— <sup>††</sup>	76.6 (72.9–79.9)
<b>Influenza (≥2 doses)<sup>¶¶¶</sup></b>	68.5 (67.0–70.0)	50.6 (47.0–54.3)**	61.4 (58.9–64.0)**	— <sup>††</sup>	77.7 (73.4–81.6)**	— <sup>††</sup>	59.5 (55.6–63.5)**
<b>Combined 7-vaccine series<sup>****</sup></b>	72.8 (71.3–74.3)	62.7 (59.3–66.1)**	69.1 (66.6–71.7)**	63.1 (53.6–72.6)**	74.4 (69.8–78.8)	— <sup>††</sup>	67.8 (63.8–71.7)**
<b>No vaccinations</b>	1.0 (0.7–1.4)	1.1 (0.6–1.6)	0.6 (0.4–0.9)**	— <sup>††</sup>	— <sup>††</sup>	— <sup>††</sup>	— <sup>††</sup>

**Abbreviations:** DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.

\* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).

<sup>†</sup> Data for the 2018 birth year are from survey years 2019, 2020, and 2021; data for the 2019 birth year are considered preliminary and are from survey years 2020 and 2021 (data from survey year 2022 are not yet available).

<sup>§</sup> Children's race/ethnicity was reported by the parent or guardian. Children identified in this report as White, Black, Asian, American Indian/Alaska Native, Native Hawaiian or other Pacific Islander, or multiple races were reported by the parent or guardian as non-Hispanic. Children identified as being of multiple races had more than one race category selected. Children identified as Hispanic might be of any race.

<sup>¶</sup> Includes children who might have received diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

\*\* Statistically significant ( $p < 0.05$ ) difference compared with the referent group.

<sup>††</sup> Estimate not available because the unweighted sample size for the denominator was  $< 30$ , or 95% CI half width/estimate  $> 0.588$ , or 95% CI half-width was  $\geq 10$ .

<sup>§§</sup> Includes children who might have received measles, mumps, rubella, and varicella combination vaccine.

<sup>¶¶</sup> Hib primary series: receipt of  $\geq 2$  or  $\geq 3$  doses, depending on product type received; full series: primary series and booster dose, which includes receipt of  $\geq 3$  or  $\geq 4$  doses, depending on product type received.

\*\*\* One dose HepB administered from birth through age 3 days.

<sup>†††</sup> Before 2020, first dose of HepA recommended at age 12-23 months, with second dose given 6-18 months after the first, depending upon the product type received. In 2020, recommendation revised to two doses between ages 12 and 23 months, at least six months apart. Since children in this analysis were vaccinated under both recommendations, coverage estimates for both  $< 24$  months and  $< 35$  months are provided.

<sup>§§§</sup> Includes  $\geq 2$  doses of Rotarix monovalent rotavirus vaccine (RV1), or  $\geq 3$  doses of RotaTeq pentavalent rotavirus vaccine (RV5). If any dose in the series is either RotaTeq or unknown, default to 3-dose series. The maximum age for the final rotavirus dose is 8 months, 0 days.

<sup>¶¶¶</sup> Doses must be at least 24 days apart (4 weeks with a 4-day grace period); doses could have been received during two influenza seasons.

\*\*\*\* The combined 7-vaccine series (4:3:1:3\*:3:1:4) includes  $\geq 4$  doses of DTaP,  $\geq 3$  doses of poliovirus vaccine,  $\geq 1$  dose of measles-containing vaccine, the full series of Hib ( $\geq 3$  or  $\geq 4$  doses, depending on product type),  $\geq 3$  doses of HepB,  $\geq 1$  dose of VAR, and  $\geq 4$  doses of PCV.